BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw an uptick in trading volume on Monday . 2,798,512 shares traded hands during mid-day trading, an increase of 33% from the previous session’s volume of 2,100,511 shares.The stock last traded at $97.66 and had previously closed at $91.99.

Several brokerages have recently weighed in on BMRN. Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $126.00 target price on shares of BioMarin Pharmaceutical in a report on Wednesday, June 1st. Royal Bank Of Canada reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, May 31st. Leerink Swann reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, June 1st. Cowen and Company reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Thursday, July 28th. Finally, Oppenheimer Holdings Inc. reiterated a “hold” rating and issued a $99.00 price objective on shares of BioMarin Pharmaceutical in a research note on Wednesday, June 1st. Three equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. BioMarin Pharmaceutical presently has a consensus rating of “Buy” and a consensus target price of $121.01.

The stock’s 50 day moving average price is $93.15 and its 200-day moving average price is $85.44. The company’s market capitalization is $16.05 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, August 4th. The company reported ($2.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by $2.09. During the same quarter in the prior year, the company earned ($0.51) EPS. The company earned $300.10 million during the quarter, compared to analysts’ expectations of $278.75 million. The business’s revenue was up 20.0% compared to the same quarter last year. Analysts anticipate that BioMarin Pharmaceutical Inc. will post ($3.96) EPS for the current year.

In other BioMarin Pharmaceutical news, VP Brian Mueller sold 287 shares of the stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $100.00, for a total transaction of $28,700.00. Following the transaction, the vice president now owns 14,260 shares in the company, valued at $1,426,000. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP George Eric Davis sold 2,167 shares of the stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $100.00, for a total value of $216,700.00. Following the transaction, the executive vice president now owns 71,158 shares in the company, valued at approximately $7,115,800. The disclosure for this sale can be found here.

A number of institutional investors recently made changes to their positions in the stock. RS Investment Management Co. LLC increased its position in shares of BioMarin Pharmaceutical by 80.2% in the fourth quarter. RS Investment Management Co. LLC now owns 99,240 shares of the company’s stock valued at $10,396,000 after buying an additional 44,180 shares during the period. I.G. Investment Management LTD. increased its position in shares of BioMarin Pharmaceutical by 20.1% in the fourth quarter. I.G. Investment Management LTD. now owns 32,380 shares of the company’s stock valued at $3,392,000 after buying an additional 5,430 shares during the period. Finally, Utah Retirement Systems increased its position in shares of BioMarin Pharmaceutical by 0.3% in the fourth quarter. Utah Retirement Systems now owns 28,781 shares of the company’s stock valued at $3,016,000 after buying an additional 100 shares during the period.

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.